Seres Health Announces $65 Million Investment from Nestlé Health Science

Seres Health Announces $65 Million Investment from Nestlé Health Science

January 6, 2015

CAMBRIDGE, Mass., January 6, 2015 /PRNewswire/ -- Seres Health, Inc., a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat diseases by restoring the function of a dysbiotic microbiome, announced today that it has completed a $65 million Series D preferred stock investment by Nestlé Health Science, a wholly-owned subsidiary of Nestlé.  Together with its recently announced $48 million Series C preferred stock financing, Seres Health had over $110 million of cash and investments at the end of 2014.

Moderna to Present at 33rd Annual J.P. Morgan Healthcare Conference

Moderna to Present at 33rd Annual J.P. Morgan Healthcare Conference

January 6, 2015

CAMBRIDGE, Mass., Jan. 6, 2015— Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that Stéphane Bancel, president and chief executive officer of Moderna, will present a company overview at the 33rd Annual J.P. Morgan Healthcare Conference.

Moderna Closes $450 Million Financing to Support Growth of Messenger RNA Therapeutics™ Platform across Diverse Therapeutic Areas

Moderna Closes $450 Million Financing to Support Growth of Messenger RNA Therapeutics™ Platform across Diverse Therapeutic Areas

January 5, 2015

CAMBRIDGE, Mass., January 5, 2015 - Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™, announced today that it has raised $450 million in new funding to support the further expansion of its mRNA Therapeutics™ platform across multiple modalities and therapeutic areas. Since the company's founding in 2011 by Flagship VentureLabs™, Moderna has secured more than $950 million in funding through financing activities and commercial partnerships.

Selecta and Skolkovo Foundation Collaboration to Develop a Synthetic Vaccine Particle in the field of Immuno-oncology

Selecta and Skolkovo Foundation Collaboration to Develop a Synthetic Vaccine Particle in the field of Immuno-oncology

December 23, 2014

$3.2 Million Grant from Skolkovo Foundation for Novel Immunotherapeutic to Target Cervical, Head and Neck Cancers Associated with HPV

Pronutria Biosciences Announces Issuance of Key Patents from USPTO on Compositions and Methods Relating to Oral Biologics

Pronutria Biosciences Announces Issuance of Key Patents from USPTO on Compositions and Methods Relating to Oral Biologics

December 18, 2014

Granted claims include composition of matter on lead products

CAMBRIDGE, Mass., Dec. 18, 2014 /PRNewswire/ -- Pronutria Biosciences, Inc., which is developing novel oral biologics to restore cellular homeostasis in a range of serious medical conditions, today announced the issuance by the United States Patent and Trademark Office (USPTO) of US Patent No. 8,809,259 and US Patent No. 8,822,412. The patents claim proteins and methods of their use covering the company's lead product candidates, including PN-107 and PN-340.

Quanterix Announces the Simoa Accelerator, an Innovation Center for Biomarker Research and Custom Assay Development

Quanterix Announces the Simoa Accelerator, an Innovation Center for Biomarker Research and Custom Assay Development

December 16, 2014

LEXINGTON, Mass.--()--Quanterix Corp

Agios Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

Agios Pharmaceuticals Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

December 16, 2014

CAMBRIDGE, Mass.Dec.

Acceleron Pharma Appoints Dr. Francois Nader to its Board of Directors

Acceleron Pharma Appoints Dr. Francois Nader to its Board of Directors

December 12, 2014

 CAMBRIDGE, Mass.--()--Acceleron Pharma Inc.

Syros Pharmaceuticals Announces New Research Published on CDK7 in Lung and Pediatric Cancers

Syros Pharmaceuticals Announces New Research Published on CDK7 in Lung and Pediatric Cancers

December 11, 2014

- Papers in Cell and Cancer Cell describe in vivo activity of CDK7 inhibitors; further validate company’s lead preclinical program -

WATERTOWN, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies, announced today the recent publication of two studies that further demonstrate the critical role of CDK7 in cancers driven by oncogenic transcription factors, including certain lung and pediatric cancers.

Syros Pharmaceuticals Presents New Data from Its Gene Control Platform at Oncology Conferences

Syros Pharmaceuticals Presents New Data from Its Gene Control Platform at Oncology Conferences

December 11, 2014

- Posters at 56th ASH Annual Meeting and 2014 San Antonio Breast Cancer Symposium highlight identification of patient subtypes and novel drug targets in acute myeloid leukemia and breast cancer -